47,95 €
47,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
24 °P sammeln
47,95 €
47,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
24 °P sammeln
Als Download kaufen
47,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
24 °P sammeln
Jetzt verschenken
47,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
24 °P sammeln
  • Format: PDF

This book comprehensively discusses the current shortcomings for delivery of classical (small) drugs, macromolecular therapeutics, and recombinant vaccine via the common intravascular and extravascular routes. It describes the synthetic/chemical engineering methods as well as recombinant, hybridoma, and phage display technologies to fabricate different types of nanoparticulate carriers and drugs. It also reveals the diversified approaches undertaken by harnessing nanotechnology to overcome the multistep extracellular and intracellular barriers and to facilitate the development of novel strategies for therapeutic delivery and imaging.…mehr

Produktbeschreibung
This book comprehensively discusses the current shortcomings for delivery of classical (small) drugs, macromolecular therapeutics, and recombinant vaccine via the common intravascular and extravascular routes. It describes the synthetic/chemical engineering methods as well as recombinant, hybridoma, and phage display technologies to fabricate different types of nanoparticulate carriers and drugs. It also reveals the diversified approaches undertaken by harnessing nanotechnology to overcome the multistep extracellular and intracellular barriers and to facilitate the development of novel strategies for therapeutic delivery and imaging.

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Dr. Ezharul Hoque Chowdhury is an associate professor and cluster leader of biomedical engineering under the Advanced Engineering Platform at Monash University (Sunway Campus). He obtained his Doctor of Engineering degree in 2003 at Tokyo Tech. Dr. Chowdhury has pioneered the development of pH-sensitive inorganic nanoparticles as smart tools for efficient and targeted intracellular delivery of genetic materials, gene-silencing elements, proteins, and classical anticancer drugs. He is currently applying this smart nanotechnology for the treatment of cancer, particularly breast carcinoma, and cardiovascular diseases, such as diabetes. Dr. Chowdhury holds six Japanese and US patents.